Companies › Abeona Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EB-101 Autologous RDEB keratinocytes transduced with retrovirus containing COL7A1 expression cass | – | Phase 3 | Epidermolysis Bullosa | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05725018 | EB-101 | Phase 3 | Epidermolysis Bullosa | Immunology | Sep 2025 |
Cash and short-term investments of $135m on 2026-09-30; operating cash outflow about $61m a year; runway about 26 months at that burn, to Dec 2028
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Edesa Biotech ALK-Abelló Kolon TissueGene Doron Therapeutics UnicoCell Biomed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.